= Emerging. More than 5 years before clinical availability. (26.55%)
= Expected to be clinically available in 1 to 4 years. (39.66%)
= Clinically available now. (33.79%)
MSACL 2020 US : Suhandynata

MSACL 2020 US Abstract

Topic: Tox / TDM / Endocrine

Podium Presentation in Room 1 on Wednesday at 11:40 (Chair: Jen Colby / Chris Koch)

Development of an LC-MS/MS Assay for the Analysis of Endogenous Cannabinoid Plasma Concentrations

Raymond Suhandynata (Presenter)
University of California San Diego

Presenter Bio(s): Ray Suhandynata, Ph.D. is a Clinical Chemistry Fellow at the University of California San Diego's Center for Advanced Laboratory Medicine, under the direction of Dr. Robert Fitzgerald. He attended the State University of New York at Stony Brook where he received his Ph.D. in Biochemistry and Structural Biology. His graduate work was performed under Dr. Nancy Hollingsworth’s mentorship, where he applied quantitative phospho-proteomics to identify kinase targets by LC-MS/MS. His post-doctoral work was performed at the Ludwig Institute for Cancer Research in San Diego, and focused applying quantitative LC-MS/MS to identify sumoylated proteins and the roles they play in chromosome segregation. In his current fellowship, he is expanding his skills in the areas of small molecule analysis and clinical method validation with future hopes to apply these skills in a clinical toxicology setting.

Authors: Raymond Suhandynata, Melissa Hoffman, Thomas Marcotte and Robert Fitzgerald
University of California, San Diego, CA


Background: The discovery of cannabinoid (CB) receptors and the growing popularity of cannabis use has sparked interest in understanding the biological function of CB receptors’ endogenous ligands, or endocannabinoids (eCBs). Most attention has focused on the physiological role of two eCBs, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG). THC and CBD are capable of functioning as CB1 and CB2 agonists and, therefore, impact important physiological processes. Widespread recreational and medical use of cannabis and CBD products underscores the importance of understanding how exogenous cannabinoids effect the endocannabinoid system. To address this, liquid chromatography – multiple reaction monitoring mass spectrometry (LC-MRM) assays have been developed to quantify AEA and 2-AG in patient plasma.

Methods: Detection of the eCBs was optimized by direct infusion ESI-MS/MS (Waters, TQ-S micro) of pure standard compounds (Cayman). Both compounds performed best in positive ion mode and at least two precursor and product ion pairs (quantifier and qualifier ions) were selected to monitor each compound. Cone voltage and collision energy optimization was performed for ion transitions monitored. Separation of analytes was achieved using reversed-phase liquid chromatography on a Waters Acquity UPLC equipped with a BEH C18 column (2.1 ID x 50 mm, 1.7 um particles) and mobile phases A and B consisting of 5 mM ammonium formate in water with 0.1% formic acid and acetonitrile with 0.1% formic, respectively. A 3.5 min gradient was used with a total run time of 5 min per sample.

Results: Collection tube type was evaluated and did not grossly affect the measured concentrations of AEA. However, the measured concentrations of 2-AG varied up to 5-fold depending on collection tube type. Based on stability of 2-AG, K-EDTA was selected as the collection tube of choice. Assay linearity was determined for each analyte using a seven point calibration curve. The linear ranges for AEA and 2-AG quantification in plasma are 0.05 to 25 ng/mL and 0.25 to 25 ng/mL, respectively. High, mid, and low concentration samples (4.0 ng/mL, 1.0 and 0.6 ng/mL) were analyzed to assess accuracy and precision. The observable bias for the high, mid, and low spiked samples were measured. In addition, stability in the auto-sampler was assessed at 24, 48, and 96 hours. Results demonstrate that AEA and 2-AG are stable in the LC auto-sampler for up to 24 hours. Sample carryover was evaluated and none was observed following injection of the highest calibrator (25 ng/mL). Within run accuracy and precision was determined in stripped plasma, indicating that calibrator and QC bias was < 20% and coefficient of variations (%CV) were <10%. Matrix effect studies revealed no matrix effects for AEA but significant interpatient matrix effects for 2-AG.

Conclusion: This AEA LC-MRM assay will be applied to patient plasma in a clinical trial assessing the therapeutic efficacy and safety of CBD therapy.

Financial Disclosure

SalaryyesDigital Proteomics
Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: